Berenberg Bank Upgrades GSK (NYSE:GSK) to “Buy”

by · The Markets Daily

GSK (NYSE:GSK – Get Free Report) was upgraded by stock analysts at Berenberg Bank from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Briefing.com reports.

A number of other equities analysts also recently weighed in on GSK. HSBC restated a “hold” rating on shares of GSK in a report on Thursday. Wall Street Zen downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Weiss Ratings lowered shares of GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Royal Bank Of Canada began coverage on shares of GSK in a research note on Tuesday, September 8th. They set a “sector perform” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of “Hold” and an average price target of $56.50.

View Our Latest Analysis on GSK

GSK Stock Performance

Shares of NYSE GSK opened at $50.07 on Tuesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The stock has a 50 day moving average price of $51.22 and a 200 day moving average price of $52.68. The stock has a market capitalization of $101.27 billion, a PE ratio of 15.66, a price-to-earnings-growth ratio of 2.02 and a beta of 0.35. GSK has a 52 week low of $39.29 and a 52 week high of $61.69.

GSK (NYSE:GSK – Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%.The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. During the same quarter in the previous year, the firm earned $0.47 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts predict that GSK will post 4.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GSK

Several institutional investors and hedge funds have recently modified their holdings of GSK. Fisher Asset Management LLC lifted its stake in shares of GSK by 3.0% during the 4th quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company’s stock worth $1,627,931,000 after buying an additional 968,370 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of GSK by 842.9% during the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock worth $49,986,000 after buying an additional 852,437 shares during the period. BI Asset Management Fondsmaeglerselskab A S grew its stake in GSK by 2,032.8% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 854,331 shares of the pharmaceutical company’s stock valued at $41,896,000 after buying an additional 814,275 shares during the last quarter. Waverly Advisors LLC grew its stake in GSK by 1,372.8% in the 2nd quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock valued at $15,233,000 after buying an additional 270,863 shares during the last quarter. Finally, Tidal Investments LLC raised its holdings in GSK by 4.6% in the 2nd quarter. Tidal Investments LLC now owns 220,236 shares of the pharmaceutical company’s stock valued at $11,545,000 after acquiring an additional 9,603 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK News Summary

Here are the key news stories impacting GSK this week:

  • Positive Sentiment: GSK agreed to acquire a trispecific T-cell engager for multiple myeloma from China-based Chimagen Biosciences for up to $750 million, including upfront and milestone payments. The deal adds a potentially differentiated immuno-oncology asset to GSK’s pipeline. Reuters article
  • Positive Sentiment: New data for Jideytro (zidesamtinib) showed a high response rate and durable disease control in first-line ROS1-positive non-small-cell lung cancer. GSK plans an expanded U.S. regulatory submission, potentially broadening the drug’s commercial opportunity. Zacks article
  • Positive Sentiment: GSK reported encouraging late-stage lung-cancer results across its pipeline. Its B7-H3 antibody-drug conjugate produced a Phase III overall-survival benefit in relapsed disease, while the risankizumab-related program reportedly reduced the risk of death by 54% in a relapsed small-cell lung cancer study. These results support GSK’s broader oncology investment, including its $10.6 billion Nuvalent acquisition. The Pharma Letter article
  • Neutral Sentiment: Management also highlighted healthcare-policy collaboration using data from China’s Greater Bay Area, but this initiative is unlikely to have a material near-term effect on earnings.
  • Negative Sentiment: GSK plans to close a German flu-vaccine manufacturing site, a restructuring decision that may improve efficiency over time but creates near-term implementation costs and underscores pressure on parts of its vaccine operations. Fierce Pharma article

GSK Company Profile

(Get Free Report)

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.

Read More